Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
April 02, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative...
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
April 01, 2024 08:00 ET
|
Annovis Bio Inc.
Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company...
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
March 20, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced...
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
February 27, 2024 08:00 ET
|
Annovis Bio Inc.
MALVERN, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel...
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
February 14, 2024 07:30 ET
|
Annovis Bio Inc.
MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
January 30, 2024 08:00 ET
|
Annovis Bio Inc.
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing...
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
January 24, 2024 08:00 ET
|
Annovis Bio Inc.
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a...
Annovis Bio to Participate in the 139th Yale CEO Summit
December 11, 2023 13:00 ET
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
December 05, 2023 07:30 ET
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...
Annovis Bio Appoints Andrew Walsh as Vice President Finance
December 01, 2023 07:30 ET
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...